Trial reportJournal of evidence-based medicine2022
Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial.
Trial report in Journal of evidence-based medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of traditional Chinese medicine for post-COVID-19 syndrome: a systematic review and meta-analysis.Journal of translational medicine · 2025Pooled it
- Post-COVID-19 fatigue: A systematic review.Frontiers in psychiatry · 2022Pooled it
- Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial.Journal of evidence-based medicine · 2022Trial
- The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.Frontiers in pharmacology · 2026Review
- Impact of Long COVID symptoms on individuals in Hong Kong: Implications for occupational therapy practices.The British journal of occupational therapy · 2025Article
- Medicinal plants for the management of post-COVID-19 fatigue: A literature review on the role and mechanisms.Journal of traditional and complementary medicine · 2025Review
- Effectiveness of Five-Element Regulatory Therapy for post-COVID syndrome: a retrospective cohort study.Frontiers in medicine · 2025Article
- Challenges in diagnosis and treatment of long COVID.Frontiers in medicine · 2025Article
- Effects of a cardiopulmonary rehabilitation programme on submaximal exercise in Tunisian patients with long-COVID19: A randomized clinical trial.Biology of sport · 2024Article
- Article
- Traditional, complementary and integrative medicine for fatigue post COVID-19 infection: A systematic review of randomized controlled trials.Integrative medicine research · 2024Review
- Advances in the application of traditional Chinese medicine during the COVID-19 recovery period: A review.Medicine · 2024Review
- Simultaneous determination of multiple components in rat plasma by UHPLC-sMRM for pharmacokinetic studies after oral administration of Qingjin Yiqi Granules.Frontiers in pharmacology · 2023Article
- The heart and SARS-CoV-2.Medicina clinica · 2022Review
- The heart and SARS-CoV-2.Medicina clinica (English ed.) · 2022Review
- Post COVID-19 burden: focus on the short-term condition.Acupuncture and herbal medicine · 2022Article
- The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.The Biochemical journal · 2022Review
- Anti-fatigue effect fromAcupuncture and herbal medicine · 2022Review
- Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)-A double-blind, randomized, and placebo-controlled clinical trial protocol.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effectiveness and safety of Qingjin Yiqi granules (QJYQ) on post-COVID-19 condition (PCC).
methodPatients who met the inclusion criteria were randomly assigned to two groups, the QJYQ group received QJYQ combined with standard rehabilitation treatments (SRTs) and the control group only received SRTs. The treatment course was 14 days. The primary outcomes were modified Medical Research Council (mMRC) scale and Borg scale, while the secondary outcomes included symptoms score and 6-minute walking distance (6MWD). The safety outcome was the incidence of adverse events.
resultsA total of 388 patients with PCC were enrolled and randomly assigned to the QJYQ group (n = 194) and the control group (n = 194). Compared to the controls, the mMRC scale was improved in the QJYQ group, which was better than that of the control group [β (95%CI): -0.626 (-1.101, -0.151), p = 0.010]. A significant improvement in Borg scale was also observed in the QJYQ group compared to the control group [β (95%CI): -0.395(-0.744, -0.046), p = 0.026]. There was no statistically significant difference in symptoms score and 6MWD between the two groups (p = 0.293, p = 0.724). No treatment-related adverse events were observed in either group.
conclusionsQJYQ can bring benefits to patients with PCC, mainly in the improvement of breathlessness and fatigue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.